The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
RNA extraction free kit to deliver results in just 45 minutes
Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
Lupin recognized the need to digitize more applications, improve scalability, decrease risk of security breaches and eliminate critical data loss
Glenmark's current portfolio consists of 174 products authorized for distribution in the U.S. marketplace and 48 ANDA's pending approval with the USFDA
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
Takeda and United Nations Global Compact Network of India (UNGCNI) join hands
The production suspension impacts commercial and clinical trial supply
Subscribe To Our Newsletter & Stay Updated
